ÓÀÀû¼¯ÍÅ

±±¾©»ùÒò×éËù£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©ÏàÖúÕ¹ÏÖÖ×ÁöÏà¹Ø¾ÞÊÉϸ°ûµ÷¿ØCD8+ T ϸ°ûÔËÆøлúÖÆ

¡¡¡¡Ö×ÁöÃâÒßÖÎÁÆΪ°©Ö¢»¼Õß´øÀ´µÄеÄÖÎÁÆÊֶκÍÏ£Íû£¬ÔÚ¶àÖÖÖ×ÁöÀàÐÍÖж¼»ñµÃÁËÀֳɵÄÓ¦Óá£Ò»²¿·Ö²¡ÈË¿ÉÒÔÏìÓ¦ÃâÒßÖÎÁƲ¢È¡µÃÀíÏëµÄÖÎÁÆЧ¹û¡£¿ÉÊÇ£¬´ó²¿·Ö²¡È˶ÔÃâÒßÖÎÁÆÎÞ·¨±¬·¢ÏìÓ¦¡£ÆäÖÐÒ»¸öÖ÷ÒªÔµ¹ÊÔ­ÓÉÊÇÆäÖ×Áö΢ÇéÐÎÖÐTϸ°ûµÄ¹¦Ð§ÒѾ­´¦ÓÚ²»¿ÉÄæµÄʧµ÷״̬¡£Ñо¿Åú×¢£¬Ö×ÁöÏà¹Ø¾ÞÊÉϸ°ûÊÇÓÕµ¼Tϸ°û¹¦Ð§Ê§µ÷µÄÖ÷Á¦¾üÖ®Ò»¡£×÷ΪÃâÒßϸ°ûµÄÒ»Ô±£¬¾ÞÊÉϸ°û½øÈëÖ×Áö΢ÇéÐÎÖкóÍùÍùÊܵ½Ö×ÁöµÄÓ°Ï죬ת±äΪÔö½øÖ×ÁöÉú³¤²¢ÒÖÖÆTϸ°û¹¦Ð§µÄ״̬£¬µ«Æäµ÷¿Ø»úÖÆÉв»ÇåÎú¡£×÷ΪÕæºËϸ°ûÖÐmRNAÉÏƷò×î¸ßµÄÐÞÊÎÀàÐÍ£¬m6AÐÞÊοÉÒÔͨ¹ýÓ°ÏìmRNAµÄÎȹÌÐÔ¼°·­ÒëЧÂʵÈÀú³Ì¶Ôϸ°û¹¦Ð§¾ÙÐÐ׼ȷµÄµ÷¿Ø¡£µ«½üÆÚµÄÊÂÇéÒ²·¢Ã÷£¬m6AÐÞÊÎϵͳÔÚ¶àÖÖÀàÐÍÖ×ÁöÖд¦ÓÚʧµ÷״̬¡£ÄÇô£¬m6AÐÞÊÎʧµ÷ÊÇ·ñÓ°ÏìÖ×ÁöÏà¹Ø¾ÞÊÉϸ°ûµÄ¹¦Ð§£¬²¢¼ÓÈëÆä¶ÔTϸ°û¹¦Ð§µÄµ÷¿ØÄØ£¿  

¡¡¡¡5ÔÂ20ÈÕ£¬ÖпÆÔº±±¾©»ùÒò×éÑо¿Ëù£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©º«¶¦Á¦´ó¾ÙÑо¿×éÍŽáÇ廪´óѧÃâÒßÑо¿ËùÐìÃÈÍŶÓ£¬ÔÚCancer CellÉϽÒÏþÁËÌâΪ¡°The loss of RNA N6-adenosine methyltransferase Mettl14 in tumor-associated macrophages promotes CD8+ T cell dysfunction and tumor growth¡±µÄÑо¿ÂÛÎÄ£¬Õ¹ÏÖÁËÌض¨Ö×ÁöÏà¹Ø¾ÞÊÉϸ°ûÑÇȺͨ¹ý±í¹Ûת¼×é²ãÃæµ÷¿ØCD8+ Tϸ°û¹¦Ð§µÄлúÖÆ£ºm6A¼×»ù»¯Ã¸METTL14ÔÚC1q+ ¾ÞÊÉϸ°ûÖеÄËðʧ£¬µ¼Ö¾ÞÊÉϸ°ûÖÐEbi3 ת¼±¾ÉÏm6AÐÞÊεĽµµÍºÍEBI3±í´ïÁ¿µÄÔöÌí£¬½ø¶øÓÕµ¼Ö×Áö½þÈóµÄCD8+ Tϸ°ûµÄ¹¦Ð§Ê§µ÷¡£ 

¡¡¡¡ÕâÏîÑо¿·¢Ã÷£¬Ö×ÁöÏà¹Ø¾ÞÊÉϸ°ûÖб£´æÒ»ÀàC1q+ ¾ÞÊÉϸ°ûÑÇȺ£¬Í¨¹ýÍâòµÄÃâÒßµ÷ÀíÊÜÌåºÍTϸ°ûÏ໥×÷Óá£ÓÐȤµÄÊÇ£¬C1q+ ¾ÞÊÉϸ°ûÑÇȺÖи»¼¯ºÍm6AÐÞÊÎÏà¹ØµÄ»ùÒòÀýÈçMettl14¡£½øÒ»²½Ì½ÌÖm6AÐÞÊÎÔÚ¾ÞÊÉϸ°ûÖеÄ×÷Ó÷¢Ã÷£¬ÔÚ¾ÞÊÉϸ°ûÖÐÌØÒìÐÔÇóýMettl14 µÄСÊó¿¹Ö×ÁöÄÜÁ¦µÍÓÚÒ°ÉúÐÍСÊó£¬Ö×Áö½þÈóµÄCD8+ Tϸ°û±ÈÀýÏÔÖøϽµ¡£µ¥Ï¸°û²âÐòÊý¾ÝÅú×¢£¬ÓëÒ°ÉúÐͱÈÕÕ×éÏà±È£¬¾ÞÊÉϸ°ûÖÐMettl14 µÄȱʧ¿Éµ¼ÖÂÃâÒß΢ÇéÐÎÖнþÈóµÄЧӦÐÔCD8+ Tϸ°ûºÍºÄ½ßÐÔTϸ°ûÇ°Ìåϸ°ûÏÔÖøïÔÌ­£¬¶ø»î»¯Òì³£ÇÒ¹¦Ð§Ê§µ÷µÄÖÐÐÄ̬CD8+ Tϸ°ûÏÔÖøÔö¶à¡£¹¦Ð§ÑéÖ¤½øÒ»²½ËµÃ÷£¬¾ÞÊÉϸ°ûÖÐMettl14 µÄȱʧµ¼ÖÂCD8+ Tϸ°ûµÄɱÉËÐÔ¹¦Ð§Ï½µ£¬²¢ÇÒÉϵ÷±í´ï¹²ÒÖÖÆÐÔÊÜÌå¡£ÕâЩЧ¹û˵Ã÷Mettl14 ȱʧµÄ¾ÞÊÉϸ°ûÍ»ÆÆÁËCD8+ Tϸ°û·Ö½âµÄƽºâ£¬¼´ÒÖÖÆЧӦÐÔCD8+ Tϸ°ûµÄ»î»¯¶ø´ÙʹCD8+ Tϸ°û¹¦Ð§Ê§µ÷¡£ 

¡¡¡¡Í¨¹ýÕûºÏÆÊÎöÒ°ÉúÐͺÍMettl14 ȱʧµÄÖ×ÁöÏà¹Ø¾ÞÊÉϸ°ûµÄm6A-seqºÍRNA-seqÊý¾Ý£¬·¢Ã÷Ebi3 mRNAÉϵÄm6AÐÞÊÎˮƽÔÚMettl14 ȱʧµÄ¾ÞÊÉϸ°ûÖÐÏÔÖø½µµÍ£¬Ebi3 mRNAˮƽºÍÂÑ°×±í´ïˮƽÏÔÖøÌá¸ß¡£EBI3ÖкͿ¹Ìåͨ¹ýÕü¾ÈMettl14 Ìõ¼þÐÔÇóýСÊóÖÐCD8+ Tϸ°ûµÄɱÉËÐÔ¹¦Ð§£¬ÏÔÖøÌá¸ßÆ俹Ö×ÁöÄÜÁ¦¡£Ð§¹ûÅú×¢£¬Mettl14 ȱʧµÄ¾ÞÊÉϸ°ûͨ¹ýÌá¸ßEBI3µÄ±í´ïÁ¿ÓÕµ¼CD8+ Tϸ°û¹¦Ð§Ê§µ÷¡£½ÓÏÂÀ´£¬ÎªÁË̽ÌÖÉÏÊö½áÂÛÊÇ·ñÊÊÓÃÓÚ²¡ÈËÖ×ÁöÑù±¾£¬Ñо¿ÕßÊ×ÏÈʹÓöàÉ«ÃâÒß×éÖ¯»¯Ñ§È¾É«ÊÖÒÕ·¢Ã÷½á³¦°©²¡È˵ÄÖ×ÁöÑù±¾ÖоÞÊÉϸ°ûÓëCD8+ Tϸ°ûµÄÁÚ½üλÖùØϵ¡£³ý´ËÖ®Í⣬Ö×Áö»ùÖÊÖÐMETTL14 µÄ±í´ïÁ¿Óëm6AÐÞÊÎˮƽÒÔ¼°CD8+ Tϸ°ûµÄ½þÈó³ÊÕýÏà¹Ø¹Øϵ¡£Ö×Áö»ùÖʵÄm6AÐÞÊÎˮƽ¸ßµÄ²¡ÈËÓëm6AÐÞÊÎˮƽµÍµÄ²¡ÈËÏà±È£¬Ö×Áö»ùÖÊÖнþÈóµÄCD8+ Tϸ°ûЧӦÐÔ¹¦Ð§¸üºÃ¡£ 

¡¡¡¡×ÛÉÏ£¬±¾Ñо¿±¨µÀÁËÖ×ÁöÏà¹Ø¾ÞÊÉϸ°ûÖÐRNA m6AÐÞÊεÄʧµ÷µ¼ÖÂEBI3±í´ïÁ¿µÄÉϵ÷£¬´ÙʹCD8+ Tϸ°û¹¦Ð§Ê§µ÷µÄлúÖÆ¡£Ñо¿Åú×¢m6AÐÞÊÎÔÚ±í¹Ûת¼²ãÃæµ÷¿Ø¾ÞÊÉϸ°ûµÄÃâÒßµ÷Àí¹¦Ð§£¬Ç¿µ÷Á˾ÞÊÉϸ°û¹¦Ð§¿ÉËÜÐÔ¿Éͨ¹ý±í¹Ûת¼¶¯Ì¬×ª±äʵÏÖ¾«×¼µ÷¿Ø¡£Ñо¿ÕßÌá³ö£¬°ÐÏòMettl14ÏÂÓÎÒÖÖÆCD8+ Tϸ°û¹¦Ð§µÄ·Ö×Ó£¬ÀýÈçEBI3£¬ÓÐÍû»Ö¸´CD8+ Tϸ°û¹¦Ð§²¢Ìá¸ßÏÖÓÐPD-1/PD-L1×è¶Ï¿¹ÌåÁÆ·¨µÄÏìÓ¦ÂÊ¡£ 

¡¡¡¡¸ÃÂÛÎÄÖУ¬ÓÀÀû¼¯ÍÅ£¨¹ú¼ÒÉúÎïÐÅÏ¢ÖÐÐÄ£©º«¶¦Á¦´ó¾ÙÑо¿Ô±ºÍÇ廪´óѧҽѧԺÐìÃÈÑо¿Ô±ÎªÂÛÎĵÄÅäºÏͨѶ×÷Õß¡£Ç廪´óѧ²©Ê¿Éú¶­Àö»Ô£¬»ùÒò×éËù²©Ê¿Éú³Â´«Ô¶ºÍÕÅÑÇΰΪÂÛÎĵÄÅäºÏµÚÒ»×÷Õߣ¬»ùÒò×éËùµÄ²©Ê¿ºó·²ÈËÝáºÍ²©Ê¿ÉúÁº¹ãºÀ£¬Ç廪´óѧ²©Ê¿Éú¹ùö¬½õ¡¢Áõß®¡¢ÀîÒàÁÖºÍËïÃÎÑ©Ò²¼ÓÈëÁË´ËÊÂÇé¡£±±¾©´óѧÖ×ÁöÒ½ÔºµÄÉòÁÕ½ÌÊÚÍŶÓ£¬±±¾©´óѧÁõ¾ýÑо¿Ô±£¬ÓÀÀû¼¯ÍÅÉú̬ÇéÐÎÑо¿ÖÐÐÄÍôº£ÁÖÑо¿Ô±ºÍÀµçâÒ㲩ʿÒÔ¼°Ö¥¼Ó¸ç´óѧUrszula DoughertyºÍ Marc B. Bissonnette¶Ô±¾ÎÄÓÐÖ÷ҪТ˳¡£

ÓÀÀû¼¯ÍÅ¡¤yl(ÖйúÓÎ)¹Ù·½ÍøÕ¾ 

¡¡¡¡Ö×ÁöÏà¹Ø¾ÞÊÉϸ°ûm6AÐÞÊÎøMettl14µÄ½µµÍ½«Éϵ÷Ebi3 mRNAµÄÎȹÌÐÔ£¬Ìá¸ßEBI3µÄÉø͸ÊͷŲ¢½øÒ»²½ÖÂʹCD8+ T cellsµÄ¹¦Ð§Ê§µ÷£¬×îÖÕÔö½øÖ×ÁöÉú³¤

¡¡¡¡ÂÛÎÄÁ´½Ó 

¸½¼þÏÂÔØ£º
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿